Scientific Program
14:00 – 14:10
WELCOME ADDRESS
Plenary Hall (Ballsaal)
Dirk Busch, Technical University of Munich, Germany
Adi Barzel, Tel-Aviv University, Israel
14:10 – 14:45
KEYNOTE LECTURE: BALANCING PERSISTENCE AND EFFECTOR FUNCTIONS IN CAR T CELLS
Plenary Hall (Ballsaal)
Chair: Adi Barzel, Tel-Aviv University, Israel
14:10 – 14:35 Presentation
Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA
14:35-14:45 – Q&A
14:45 – 16:00
SESSION 1: NOVEL CLINICAL APPROACHES AND COMBINATION THERAPIES
Plenary Hall (Ballsaal)
Chair: Luigi Naldini, San Raffaele Telethon Institute for Gene Therapy, Italy
14:45 – 15:00
SINGLE-CELL RNA-SEQ DEVELOPMENT OF NOVEL CELLULAR THERAPIES
Sebastian Kobold, Ludwig Maximilian University of Munich, Germany
15:00 – 15:15
COMBINED ENGINEERING OF TUMOR-ASSOCIATED MACROPHAGES AND T CELLS TO ESTABLISH ANTI-CANCER IMMUNITY
Luigi Naldini, San Raffaele Telethon Institute for Gene Therapy, Italy
15:15 – 15:25
COMBINATION OF TCR-T CELLS COENGINEERED TO SECRETE SIRP-ALPHA DECOYS AND ANTI-TUMOR ANTIBODIES TO AUGMENT MACROPHAGE PHAGOCYTOSIS
Evangelos Stefanidis, Ludwig Institute for Cancer Research, University of Lausanne and Lausanne University Hospital, Switzerland
15:25 – 16:00
Panel discussion
16:00 – 16:45
COFFEE BREAK, EXHIBITION AND POSTER PRESENTATIONS
Exhibition & Networking Area (Grosser Saal)
16:45 – 18:20
SESSION 2: SUPERPOWERED LYMPHOCYTES
Plenary Hall (Ballsaal)
Chair: George Coukos, Lausanne University Hospital, Switzerland
16:45 – 17:00
SENSITIVE AND SELECTIVE TARGETING OF HETEROGENEOUS TUMOR CELLS WITH ENGINEERED T CELLS
Stanley Riddell, Fred Hutchinson Cancer Research Center, USA
17:00 – 17:15
PREPARATION IS EVERYTHING: HOW TO GET THE MOST OUT OF ELECTROPORATION FOR T-CELL ENGINEERING
Renata Stripecke, University Hospital Cologne, Germany
(Supported By Maxcyte)
17:15 – 17:30
ENGINEERING LYMPHOCYTES TO OVERCOME EXHAUSTION
George Coukos, Lausanne University Hospital, Switzerland
17:30 – 17:40
EMPOWERING CYTOTOXICITY OF CAR T CELLS TO ENHANCE ANTI-CANCER RESPONSES
Victor Peperzak, University Medical Center Utrecht, Netherlands
17:40 – 18:20
Panel discussion
18:20 – 20:00
TOP 10 POSTERS – PRESENTATIONS & WELCOME RECEPTION
Exhibition & Networking Area (Grosser Saal)
Chair: Adam Keren, Tel Aviv University, Israel
18:40 – 18:45
NKG2D-CAR MEMORY T CELLS TARGET PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN VITRO AND IN VIVO BUT FAIL TO ELIMINATE LEUKEMIA INITIATING CELLS
Lucía Fernández, National Cancer Research Center, Spain
18:45 – 18:50
FCYRIIA-SPECIFIC DARPINS DISPLAYED ON VIRAL VECTORS FOR HIV GENE THERAPY
Samuel Theuerkauf, Paul Ehrlich Institute, Germany
18:50 – 18:55
THE INTEGRATED MULTI-OMIC CHARACTERIZATION OF “OFF-THE-SHELF” CD19-CAR-T CELLS ALLOWS THE IDENTIFICATION OF ENGINEERED CELLS ENDOWED WITH SUPERIOR ANTI-TUMOR FITNESS AND LOWER PRO-INFLAMMATORY ACTIVITY
Cristina Maccalli, Sidra Medicine, Qatar
18:55 – 19:00
ISOLATION AND CHARACTERIZATION OF NEOEPITOPE-SPECIFIC TCRS FOR T CELL THERAPY IN GASTROINTESTINAL CANCER
Linda Warmuth, Technical University of Munich, Germany
19:00 – 19:05
THIRD-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS IN ADULT ALL AND NHL PATIENTS
Michael Schmitt, University Hospital Heidelberg, Germany
19:05 – 19:10
BANANA LECTIN EXPRESSING CAR T CELLS ENHANCE ANTI-TUMOR ACTIVITY AGAINST HETEROGENOUS SOLID TUMORS
Katie McKenna, Baylor College of Medicine, United States
19:10 – 19:15
COMBINATION OF CD4+ AND CD8+ T CELLS IN T CELL THERAPY OF HBV INFECTION ENHANCES VIRUS CONTROL IN VIVO BY INCREASING IFN-G AND TNF-A SECRETION
Sophia Schreiber, Technical University of Munich, Germany
19:15 – 19:20
IMMUNOTHERAPY TARGETING MUTANT NUCLEOPHOSMIN-1 ON ACUTE MYELOID LEUKEMIA
Georgia Koutsoumpli, Leiden University Medical Center, Netherlands
19:20 – 19:25
SYNTHETIC DUAL-COSTIMULATION FOR TCR AND TCR-LIKE TARGETED CELL THERAPIES
Anton Dobrin, Memorial Sloan Kettering Cancer Center, United States
19:25 – 19:30
THERAPEUTIC GENE EDITING OF T CELLS CORRECTS CTLA4 INSUFFICIENCY
Thomas Fox, University College London, United Kingdom
09:00 – 10:10
SESSION 3: NON VIRAL CAR/TCR ENGINEERING
Plenary Hall (Ballsaal)
Chair: Chiara Magnani, University of Zurich, Switzerland
09:00 – 09:15
NON-VIRAL ENGINEERING OF THERAPEUTIC CELLS WITH THE SLEEPING BEAUTY TRANSPOSON SYSTEM
Zoltan Ivics, Paul-Ehrlich-Institut, Germany
09:15 – 09:30
ACADEMIC VIRUS-FREE CAR T-CELL DEVELOPMENT
Chiara Magnani, University of Zurich, Switzerland
09:30 – 09:40
PERSISTENT GENETIC MODIFICATION OF HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS USING S/MAR DNA NANOVECTORS
Patrick Derigs, German Cancer Research Center, Germany
09:40 – 10:10
Panel discussion
10:10 – 10:50
COFFEE BREAK, EXHIBITION, MEET THE EXPERT & POSTER PRESENTATIONS
Exhibition & Networking Area (Grosser Saal)
10:25 – 10:40
Meet the Expert: Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA
10:50 – 12:15
SESSION 4: UNIVERSAL DONOR CELLS & ADVANCED TCR ENGINEERING
Plenary Hall (Ballsaal)
Chair: Dirk Busch, Technical University of Munich, Germany
10:50 – 11:10
KEYNOTE LECTURE: GENOME EDITING FOR CANCER IMMUNOTHERAPY
Chiara Bonini, Vita-Salute San Raffaele University, Italy
11:10 – 11:25
ADVANCED TCR ENGINEERED T CELLS FOR THE TREATMENT OF INFECTIONS AND CANCER
Dirk Busch, Technical University of Munich, Germany
11:25 – 11:40
ENHANCED T-CELLS FOR IMMUNOTHERAPY WITH IMPROVED TCRs AND REDIRECTED METABLOLISM
Cyrille Cohen, Bar-Ilan University, Israel
11:40 – 11:50
REDIRECTING TCR SPECIFICITY IN REGULATORY T CELLS TOWARD CLASS I HLA-RESTRICTED ISLET ANTIGENS
Raphael Porret, University Hospital of Lausanne, Switzerland
11:50 – 12:15
Panel discussion
12:15 – 13:45
LUNCH BREAK, EXHIBITION, INDUSTRY & POSTER PRESENTATIONS
Exhibition & Networking Area (Grosser Saal)
13:45 – 15:30
LATEST UPDATES AND PARTNERSHIP POTENTIAL
Industry Supported Session
Plenary Hall (Ballsaal)
Chair: Adi Barzel, Tel Aviv University, Israel
13:45 – 14:00
TUMOR INFILTRATING LYMPHOCYTES FROM PEDIATRIC SOLID TUMORS EXPANSION IN G-REX DEVICE AND A THREE-SIGNAL-BASED METHOD
África González Murillo, Foundation for Biomedical Research, The Niño Jesús University Children’s Hospital, (supported by ScaleReady)
14:00 – 14:15
T-CELL KILLING ASSAYS WITH LIVECYTE, LABEL-FREE EFFECTOR CELL TRACKING PROVIDES A KINDER INSIGHT INTO IMMUNE-CELL POLICING
Peter Djali, Head of European Business Development, Phase Focus, UK
14:15 – 14:30
ADVANCING THE FIELD THROUGH PARTNERSHIPS: THE GOCART COALITION
Christian Chabannon, GO-CART Coalition, France
14:30 – 15:00
ACHIEVING FLEXIBILITY AND SCALABILITY IN CELL THERAPY MANUFACTURING THROUGH OPTIMIZED CELL ISOLATION AND ACTIVATION
Hany Meås, Thermo Fisher Scientific, Norway
15:00 – 15:30
Panel discussion
15:30 – 15:40
SHORT BREAK
15:40 – 16:50
SESSION 5: BEYOND ALPHA-BETA T CELLS
Plenary Hall (Ballsaal)
Chair: Giulia Casorati, San Raffaele Hospital, Italy
15:40 – 15:55
γδT CELL-INSPIRED THERAPIES: FROM BENCH TO CLINICAL DATA
Jurgen Kuball, University Medical Center Utrecht, Netherlands
15:55 – 16:10
REDIRECTING T AND iNKT CELLS AGAINST CD1C EXPRESSING LEUKEMIA FOR ADOPTIVE IMMUNOTHERAPY
Giulia Casorati, San Raffaele Hospital, Italy
16:10 – 16:20
TCR-ENGINEERED INKT CELLS INDUCE ROBUST ANTI-TUMOR RESPONSE BY DUAL TARGETING CANCER AND SUPPRESSIVE MYELOID CELLS
Gloria Delfanti, San Raffaele Scientific Institute, Italy
16:20 – 16:50
Panel discussion
16:50 – 17:30
COFFEE BREAK, EXHIBITION, MEET THE EXPERT & POSTER PRESENTATIONS
Exhibition & Networking Area (Grosser Saal)
17:05 – 17:20
Meet the Expert: Stanley Riddell, Fred Hutchinson Cancer Research Center, USA
17:30 – 19:10
SESSION 6: UPDATED CLINICAL DATA
Plenary Hall (Ballsaal)
Chair: Claire Roddie, University College London, UK
17:30 – 17:45
BETTER TARGETS, BETTER TARGETING: EVOLUTION OF THE UCL CAR-T PROGRAMME
Claire Roddie, University College London, UK
17:45 – 18:00
NEW TARGETS AND TECHNOLOGIES FOR CAR T CELLS
Michael Hudecek, University Hospital Würzburg, Germany
18:00 – 18:15
MESOTHELIN-TARGETED CAR T-CELL THERAPY TRIALS
Prаsad Adusumilli, Memorial Sloan Kettering Cancer Center, USA
18:15 – 18:30
IMMUNE DYSREGULATION DETERMINES OUTCOME POST CD19 CART IN LYMPHOMA
Marion Subklewe, Ludwig-Maximilians-University Munich, Germany
18:30 – 18:40
PHASE 1/2 MULTICENTER CLINICAL TRIAL OF DONOR SPECIFIC TOLERANCE INDUCTION IN LIVING DONOR LIVER TRANSPLANTATION VIA ENGINEERED T CELLS WITH SUPPRESSING FUNCTIONS
Yui Maehara, Juntendo University, Japan
18:40 – 19:10
Panel discussion
08:30 – 09:40
SESSION 7: TARGETING NON-MALIGNANT DISEASES
Plenary Hall (Ballsaal)
Chair: Samik Basu, Cabalettabio, USA
08:30 – 08:45
TCR ENGINEERING OF TREGS TO TREAT MULTIPLE SCLEROSIS
Hans Stauss, University College London, UK
08:45 – 09:00
CD19 CAR T-CELL THERAPY FOR AUTOIMMUNE DISEASE
Samik Basu, Cabalettabio, USA
09:00 – 09:10
MRNA TECHNOLOGY FOR THE DEVELOPMENT OF CAR-T CELLS TARGETING FIBROTIC DISEASES
Sandro Bräuning, Fraunhofer Institute for Cell Therapy and Immunology IZI, Germany
09:10 – 09:40
Panel discussion
09:40 – 10:50
SESSION 8: SELECTED ABSTRACTS FOR ORAL PRESENTATION
Plenary Hall (Ballsaal)
Chair: Dirk Busch, Technical University of Munich, Germany
09:40 – 09:50
SELECTIVE DEPLETION OF ALLOREACTIVE B CELLS IN SOLID ORGAN TRANSPLANTATION: CHIMERIC ALLO-ANTIGEN-SPECIFIC T CELLS OVERCOMING REJECTION BY ANTIBODIES (CORA-TS)
Anna Christina Dragon, Hannover Medical School, Germany
09:50 – 10:00
INFECTED HEPATOCYTE CLEARANCE AND SUSTAINED TUMOR REGRESSION BY HBSAG-SPECIFIC TCR-T THERAPY FOR HBV-RELATED HCC
Karin Wisskirchen, Helmholtz Munich, Germany
10:00 – 10:10
DEVELOPING NOVEL TARGETING CARS FOR GLIOBLASTOMA
Ryan Cross, Walter and Eliza Hall Institute of Medical Research, Australia
10:10 – 10:20
GD2.CAR T-CELLS AUGMENTED WITH A CONSTITUTIVELY ACTIVE INTERLEUKIN-7 RECEPTOR FOR TREATMENT OF PEDIATRIC CNS TUMORS
Bilal Omer, Baylor College of Medicine, United States
10:20 – 10:50
Panel discussion
10:50 – 11:30
COFFEE BREAK, EXHIBITION, MEET THE EXPERT & POSTER PRESENTATIONS
Exhibition & Networking Area (Grosser Saal)
11:05 – 11:20
Meet the Expert: Luigi Naldini, San Raffaele Telethon Institute for Gene Therapy, Italy
11:30 – 12:40
SESSION 9: IN VIVO T CELL ENGINEERING
Plenary Hall (Ballsaal)
Chair: Adi Barzel, Tel Aviv University, Israel
11:30 – 11:45
IN VIVO ENGINEERING OF B CELLS AND T CELLS
Adi Barzel, Tel Aviv University, Israel
11:45 – 12:00
SURFACE ENGINEERED GENE VECTORS FOR IN VIVO CAR T CELL GENERATION
Christian Buchholz, Paul Ehrlich Institute, Germany
12:00 – 12:10
MULTI-OMICS INFORMED ENHANCEMENT OF CAR GENE DELIVERY BY RAPAMYCIN-INDUCED REDUCTION OF ANTIVIRAL MECHANISMS AGAINST T-CELL TARGETED LENTIVIRAL VECTORS
Elham Adabi, Paul Ehrlich Institute, Germany
12:10 – 12:40
Panel discussion
12:40 – 13:00
SESSION 10: BEST POSTER ANNOUNCEMENT & CONFERENCE CLOSURE
Plenary Hall (Ballsaal)
Moderators: Adi Barzel, Tel-Aviv University, Israel
Dirk Busch, Technical University of Munich, Germany
12:40 – 12:50
Announcement of the top 3 Posters
12:50 – 12:55
Presentation on stage of the BEST Poster ranked 1st
12:55 – 13:00
Summary of the event and closing words by the Conference Co-chairs